{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"3"}],"title":"Progression of Disease (POD)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"title":"Not Evaluable"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}],"title":"Stable Disease/Progression of Disease (SD/POD)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"description":"Response rate as defined by complete remission, complete remission unconfirmed, partial remission, positron emission tomography (PET)-negative partial remission, stable disease, and progressive disease (Phase II)","groups":[{"description":"Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 4 mg/m2/day and will be escalated to higher dose levels.","id":"OG000","title":"4 mg/m2/Day Clofarabine"},{"description":"Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 8 mg/m2/day and will be escalated to higher dose levels.","id":"OG001","title":"8 mg/m2/Day Clofarabine"},{"description":"Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 13.2 mg/m2/day and will be escalated to higher dose levels.","id":"OG002","title":"13.2 mg/m2/Day Clofarabine"},{"description":"Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 20 mg/m2/day and will be escalated to higher dose levels.","id":"OG003","title":"20 mg/m2/Day Clofarabine"},{"description":"Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 28 mg/m2/day and will be escalated to higher dose levels.","id":"OG004","title":"28 mg/m2/Day Clofarabine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Evaluable participants with Non-Hodgkin's Lymphoma","reportingStatus":"POSTED","timeFrame":"2 years","title":"Response Rate for Participants With Non-Hodgkin's Lymphoma","type":"PRIMARY","unitOfMeasure":"Participants"}